Retatrutide Side Effects: Complete 2026 Guide With Phase 2 + 3 Trial Data

Direct answer: The most common retatrutide side effects are gastrointestinal — nausea hits 14–60% of users depending on dose in Phase 2, and 43.2% at the 12 mg dose in the Phase 3 TRIUMPH-4 trial. Vomiting reaches 26% at 12 mg, dysesthesia (altered skin sensation) affects 20.9% at 12 mg in Phase 3, and heart rate rises 5–10 bpm on average. Discontinuation due to retatrutide side effects runs 6–18% across trial doses. Most retatrutide side effects spike during titration and resolve at stable maintenance dose — the patients who quit are usually the ones who push escalation too fast.

43.2% Nausea rate at 12 mg in TRIUMPH-4 Phase 3

20.9% Dysesthesia at 12 mg — the side effect most articles skip

4% Serious adverse event rate — identical to placebo

GI effects dominate the retatrutide side effects profile — nausea, vomiting, diarrhea, constipation. All four show a dose-dependent pattern that peaks during escalation and then settles.
Phase 3 confirms Phase 2 patterns — TRIUMPH-4 (445 patients, 68 weeks) replicated the GI signal with slightly higher absolute numbers than Phase 2 at the same doses, suggesting the longer trial duration unmasked steady-state rates.
Dysesthesia is unique to retatrutide — about 1 in 5 patients on 12 mg report altered skin sensation. Mild, rarely causes discontinuation, but worth knowing.
Heart rate rises modestly — 5–10 bpm dose-dependent, peaks around week 24, then declines. No major adverse cardiovascular events (MACE) observed in trials.
Serious retatrutide side effects are rare — the serious AE rate is 4% on retatrutide and 4% on placebo. Pancreatitis and gallbladder complications are tracked but not significantly elevated.
Discontinuation is the meaningful endpoint — 7–9% in Phase 2, 12–18% in longer Phase 3 trials. Slow titration is the single biggest variable separating completers from quitters.

Retatrutide side effects follow a predictable arc that almost every patient repeats: rough during the first 1–2 weeks after each dose increase, then steadily better at a stable dose. The problem is that most people don't know that going in, and they panic and quit right when their body would have adapted.

Retatrutide Side Effects: The Complete List With Trial Frequencies

This is the single table most people come here for. Pooled data from the Phase 2 TRIUMPH (Jastreboff et al., NEJM 2023; 338 participants, 48 weeks) and Phase 3 TRIUMPH-4 trials (445 participants, 68 weeks) at the most-studied 12 mg dose:

Retatrutide Side Effect	Phase 2 Rate (12 mg)	Phase 3 Rate (12 mg)	Placebo	Severity
Nausea	60%	43.2%	10.7%	Mostly mild–moderate
Vomiting	26%	20.9%	0.0%	Mild–moderate
Diarrhea	15%	33.1%	13.4%	Mostly mild
Constipation	16%	25.0%	8.7%	Mild–moderate
Decreased appetite	14%	~25%	3%	Mild (often a goal)
Dysesthesia (skin tingling)	3–14%	20.9%	0.7%	Mild
Hyperesthesia (skin sensitivity)	3–14%	~7%	1%	Mild
Headache	<1%	Reported low	—	Mild
Fatigue	4–12%	~10%	4%	Mild
Injection site reactions	1–8%	2–8%	0%	Mild
Cardiac arrhythmias	2–11%	~6%	2–3%	Mostly clinically minor
Heart rate increase	+5–10 bpm	+5–10 bpm	Negligible	Peaks week 24, declines
Pancreatitis	~0.4–2%	~0.4%	0%	Serious — rare
Gallbladder issues	1–2%	~1.1%	0%	Serious — uncommon
Hypoglycemia	0%	0% standalone	0%	Risk rises with insulin/SU
Allergic / hypersensitivity	3–13%	Similar	3%	Mostly mild

The Phase 2 vs Phase 3 differences are mostly about trial length. Phase 3's 68-week duration captures more late-emerging diarrhea and constipation than Phase 2's 48 weeks. The headline nausea number actually drops in Phase 3 because more patients have settled past the titration phase by the time the rate is measured.

Retatrutide Side Effects: Phase 2 vs Phase 3 Data Side-by-Side

Most retatrutide content online still cites Phase 2 numbers exclusively. Phase 3 TRIUMPH-4 results changed the picture in three important ways.

Nausea Looks Less Severe Than the Phase 2 Headline

The Phase 2 trial reported nausea at 60% for 12 mg, which became the most-quoted retatrutide side effects statistic. Phase 3 TRIUMPH-4 reported 43.2% at the same dose. The difference isn't because the drug got safer — it's that Phase 3 measured cumulative events over 68 weeks where a much larger share of patient-time is spent at stable maintenance dose rather than escalation peaks.

For a patient deciding whether to start retatrutide, the Phase 3 number is the more relevant one. The Phase 2 60% reflects the worst weeks, not the average experience.

Diarrhea Was Underestimated in Phase 2

Phase 2 reported 15% diarrhea at 12 mg. Phase 3 TRIUMPH-4 reported 33.1%. The longer trial caught a slower-emerging effect that Phase 2 missed.

Dysesthesia Was Almost Invisible in Phase 2

This is the most dramatic Phase 2 vs Phase 3 difference. Phase 2 reported altered skin sensation in 3–14% of patients. Phase 3 TRIUMPH-4 reported 20.9% dysesthesia at 12 mg — 1 in 5 patients. Phase 3's better dermatologic data collection caught what Phase 2 missed.

Dysesthesia is one of the retatrutide side effects most articles still don't mention because they were written from Phase 2 data only.

Meta-Analysis: Pooled Retatrutide Side Effects Across All Trials

A 2024 systematic review and meta-analysis in PMC pooled three randomized trials covering 878 patients total (748 retatrutide, 130 placebo). The pooled relative risks give the cleanest cross-trial picture of retatrutide side effects:

Retatrutide Side Effect	4 mg vs placebo (RR)	8 mg vs placebo (RR)	12 mg vs placebo (RR)
Any adverse event	1.11 (NS)	1.23 (P=0.007)	1.34 (P<0.0001)
Nausea	2.69 (sig)	4.27 (sig)	4.00 (sig)
Vomiting	4.62 (sig)	8.13 (sig)	8.98 (sig)
Diarrhea	1.64 (NS)	2.51 (sig)	2.04 (sig)
Constipation	4.41 (sig)	4.17 (sig)	4.41 (sig)
Decreased appetite	3.28 (sig)	3.68 (sig)	4.64 (sig)
Discontinuation for AE	2.62 (NS)	4.45 (P=0.03)	6.70 (P=0.002)

The meta-analysis lands on three clear messages about retatrutide side effects:

Vomiting is the most disproportionately elevated GI event — relative risks of 4.6× to 9× vs placebo. This is the side effect that drives most early discontinuations.
Headache, dyspepsia, and abdominal pain are NOT significantly elevated — these aren't actually retatrutide side effects at any dose tested.
Discontinuation risk scales exponentially with dose — 4 mg has only mild excess discontinuation vs placebo; 12 mg has 6.7× the placebo discontinuation rate.

The pooled weight-loss number was −14.33% body weight across doses, with −16.90% at 12 mg specifically — high enough that the GI tolerability trade-off has obvious appeal.

Heart Rate: The Retatrutide Side Effect Worth Tracking Actively

GLP-1, GIP, and glucagon receptor activation all influence sympathetic tone. The net result is a modest, dose-dependent heart rate increase that shows up consistently across trials.

Dose	Average HR Increase	Peak Timing	Pattern
4 mg	+3–5 bpm	Week 12–16	Returns to baseline by week 24
8 mg	+5–8 bpm	Week 16–24	Slow return; modest plateau
12 mg	+5–10 bpm	Week 24	Declines through weeks 36–48

What the data shows specifically:

Maximum average elevation was +6.7 bpm at 12 mg in Phase 2 at week 24
Rates declined through weeks 36–48 as the body adapted
A subset (2–11% across doses) reported mild arrhythmias vs 2% on placebo
No major adverse cardiovascular events (MACE) were observed — no heart attacks, strokes, or CV deaths attributable to retatrutide
Patients on retatrutide saw blood pressure improvements (−9.88 mmHg systolic, −3.88 mmHg diastolic in the meta-analysis) — net cardiovascular load went down, not up

For most patients this is one of the lower-priority retatrutide side effects to worry about. If you have pre-existing arrhythmia, heart failure, or untreated high resting heart rate, it deserves a conversation with the prescriber.

Dysesthesia: The Retatrutide Side Effect Most Articles Miss

Dysesthesia is altered skin sensation — tingling, burning, "pins and needles," heightened pressure sensitivity, or sensitivity to heat or cold. It is unique to retatrutide among the GLP-1 class and appears tied to the glucagon receptor component (semaglutide and tirzepatide don't show this signal).

Phase 3 TRIUMPH-4 reported dysesthesia in:

0.7% of placebo patients
8.8% of 9 mg retatrutide patients
20.9% of 12 mg retatrutide patients

A separate but related effect — hyperesthesia (heightened skin sensitivity) — appeared in 3–14% across doses vs 1% on placebo.

Key facts about dysesthesia as a retatrutide side effect:

Mild in most cases — patients describe it as "weird but not painful"
Rarely causes treatment discontinuation
Resolves at stable dose for many patients
Mechanism is not fully understood — likely related to glucagon receptor activity in peripheral nerves
More common in patients with pre-existing peripheral neuropathy or longstanding diabetes

If dysesthesia becomes severe, persistent, or painful (vs simply odd), tell the prescriber. The default response is to hold the current dose rather than escalating further; dose reduction is rarely needed.

Bone Fracture and Kidney Stone Concerns

Two specific concerns have surfaced in Phase 2 and 3 data that deserve their own discussion:

Bone Fractures and Bone Density Loss

Rapid weight loss of any kind reduces bone mineral density. With retatrutide producing 24% average weight loss in Phase 2 and even higher numbers in some Phase 3 subgroups, the bone effects are larger than seen with most other anti-obesity drugs.

Specific concerns reported in trial follow-up and expert commentary:

Bone fractures reported during Phase 2/3 trials at higher rates than placebo (specific rates being characterized in long-term follow-up)
Lean body mass loss of 20–30% of total weight lost without resistance training
Older adults at highest baseline fracture risk show the largest absolute change

Dr. John Batsis (University of North Carolina) on retatrutide and rapid weight loss: "How much is too much weight loss is unknown, and we really need additional data and need studies to look at that... We need to be mindful of how much to push. Just because we can, doesn't mean we should."

Kidney Stones

At least one Phase 2 participant developed kidney stones after losing roughly one-third of body weight in eight months. The proposed mechanism is dehydration from GI side effects combined with metabolic shifts during very rapid weight loss. Prevention:

Hydrate aggressively — 80+ oz water daily, more during titration weeks
Don't skip electrolytes — sodium, potassium, magnesium losses are real
Monitor urine color (target light straw, not dark amber)
If stones run in the family or you've had one before, mention it before starting

These aren't traditional pharmacological retatrutide side effects — they're metabolic consequences of the weight-loss velocity the drug produces. The risk applies to anyone losing weight that fast, which is part of why slow, monitored progression matters.

Women-Specific Retatrutide Side Effects: Menstrual Cycle, Fertility, Hair, Contraception

The core retatrutide side effects list is identical for women and men. What differs is the downstream impact on hormone-sensitive systems.

Menstrual Cycle Changes

Retatrutide has not been shown to directly act on reproductive hormones. But rapid weight loss, caloric restriction, and insulin sensitivity shifts absolutely affect period timing and flow. Common patterns:

Missed or delayed periods during aggressive weight loss weeks — especially when calories drop below maintenance significantly
Lighter flow as body fat reduces (estrogen production drops with adipose loss)
Cycle normalization in PCOS patients as insulin sensitivity improves — a beneficial side effect for some users

If periods stop entirely for 3+ months, talk to a clinician. This is functional hypothalamic amenorrhea territory — fixable, but not normal.

Hair Shedding

Hair loss is one of the most-searched retatrutide side effects, and it's almost always telogen effluvium — a temporary shedding triggered by the metabolic stress of rapid weight loss, not direct drug toxicity. Pattern:

Onset 2–3 months after a steep weight-loss period
Diffuse shedding (not patchy)
Resolves on its own once weight stabilizes
Worse with low protein intake during the loss period

The drug is not "causing" hair loss; the speed of the weight loss is. Protein at 1.2–1.6 g/kg of body weight, adequate iron, and slower titration all reduce the shedding intensity.

Oral Contraceptive Absorption

GLP-1 class medications slow gastric emptying. This can theoretically reduce absorption of oral contraceptives, particularly during the first weeks of treatment and after each dose increase.

Practical guidance:

A barrier method backup (condom, diaphragm) is reasonable for the first 4 weeks of treatment and for 4 weeks after each dose increase
Persistent vomiting within 4 hours of an oral contraceptive counts as a missed pill — use backup that cycle
IUDs, implants, and depot injections are unaffected — they don't depend on oral absorption

Pregnancy

Retatrutide should not be used during pregnancy. The drug must be stopped at least 2 months before trying to conceive to allow full washout. If pregnancy occurs unexpectedly, discontinue immediately and contact a prescriber.

This is not a "we'll be cautious" recommendation — it's a hard stop based on animal data suggesting fetal harm.

Retatrutide Side Effects vs Semaglutide vs Tirzepatide

A frequent question: are retatrutide side effects materially worse than what people see on Ozempic/Wegovy or Mounjaro/Zepbound? Here is the head-to-head data at top doses:

Side Effect	Retatrutide (1–60% range)	Tirzepatide (12–18%)	Semaglutide (~44%)
Nausea	14–60%	12–18%	44%
Vomiting	3–26%	5–9%	9–24%
Diarrhea	9–33%	12–17%	30%
Constipation	6–25%	6–7%	24%
Fatigue	4–12%	4–8%	11%
Headache	<1%	3–5%	14%
Dysesthesia	Up to 21%	Rare	Rare
Discontinuation for AE	7–18%	6–8%	5–7%

The honest read:

Retatrutide side effects are somewhat heavier than tirzepatide at top doses, mostly driven by the glucagon receptor component
Comparable to semaglutide at top doses on nausea, lower on headache and fatigue
Dysesthesia is uniquely retatrutide — semaglutide and tirzepatide don't show this
Discontinuation is higher, but the weight-loss benefit is also larger (24% vs 21% vs 15%) — most patients reach a different cost-benefit conclusion than the table alone suggests

The Retatrutide Side Effects Timeline: What to Expect and When

A typical patient's experience of retatrutide side effects follows a recognizable arc:

Weeks	What's Happening	Side Effect Profile
1–2	First dose (typically 0.5 or 2 mg)	Mild nausea, food noise reduction. Appetite drops sharply.
3–4	Body adapting to starting dose	Nausea fading, energy normalizes, weight loss begins.
5–8	First titration step	Nausea returns briefly after each escalation. Vomiting most likely here.
9–12	Mid-dose plateau	Side effects settle as body adapts. Heart rate uptick visible on smart watches.
13–24	Continued titration to maintenance	Each escalation produces a 1–2 week side effect spike.
24–36	Maintenance dose reached	Side effects generally minimal at stable dose. Dysesthesia may appear if not already.
36–68	Long-term maintenance	Most retatrutide side effects have resolved or stabilized. Weight loss continues.

The single biggest predictor of completing treatment is whether the escalation pace matched the patient's tolerance. Pushing escalation on schedule when GI symptoms are still active is the most common cause of discontinuation.

How to Manage Retatrutide Side Effects: Practical Strategies

Most retatrutide side effects are manageable with predictable interventions:

Nausea Management

Inject at night. Peak nausea hits 12–24 hours after dose; sleeping through it dramatically improves perceived tolerability.
Smaller, lower-fat meals. Fat slows gastric emptying further and worsens nausea on a GLP-1.
Avoid alcohol for 48 hours after each dose. Compounds nausea, dehydration, and reflux.
Stay upright for 1–2 hours after eating. Helps gastric content move.
Anti-emetics as needed — ondansetron or metoclopramide on prescription; ginger and B6 OTC.

Vomiting Management

Don't escalate the dose until vomiting has been absent for 7+ days.
Hydration is non-negotiable — sip electrolyte fluids continuously rather than chugging water.
Hold the dose if vomiting is preventing meals or fluid intake. This is not failure — it's the standard protocol.

Constipation Management

Fiber + fluids. Soluble fiber (psyllium, oats, chia) plus 80+ oz water daily.
Magnesium glycinate or citrate at bedtime helps without harsh stimulant laxatives.
Walking after meals maintains gut motility.

Heart Rate Management

Track resting heart rate weekly on a smart watch or BP cuff
Discuss with prescriber if increase exceeds 15 bpm sustained for 4+ weeks
Caffeine reduction during titration weeks can help if HR feels uncomfortable

Dysesthesia Management

Most cases self-resolve at stable dose
Hold escalation if onset is during titration
B-complex vitamin support is reasonable but not strongly evidence-based
Severe or painful dysesthesia warrants prescriber evaluation

Rare but Serious Retatrutide Side Effects to Know

These are uncommon but worth recognizing immediately if they occur:

Pancreatitis

Severe upper abdominal pain radiating to the back, with persistent nausea and vomiting, is the classic presentation. Trial rate of confirmed pancreatitis was approximately 0.4% at 12 mg — rare but serious. Risk is higher in patients with:

Prior pancreatitis history
Gallstones (current or recent)
Heavy alcohol use
Triglycerides over 500 mg/dL

This is an ER visit, not a wait-and-see symptom.

Gallbladder Disease

Cholelithiasis and cholecystitis rates ran approximately 1.1% in Phase 3 retatrutide arms vs 0% on placebo. Symptoms: right upper quadrant pain (especially after fatty meals), nausea, jaundice. Risk is higher with rapid weight loss — another argument for slower titration.

Allergic / Hypersensitivity Reactions

Skin rash, itching, swelling reported in 3–13% across doses vs 3% on placebo. Most are mild. Anaphylaxis is a known rare risk for any injectable protein — facial/throat swelling or difficulty breathing is a 911 emergency.

Acute Kidney Injury

Not a direct drug effect — but dehydration from severe vomiting/diarrhea can precipitate AKI, especially in older adults or those on diuretics. Aggressive hydration during early titration weeks is the prevention.

Thyroid C-Cell Tumors (Boxed Warning)

Rodent studies showed C-cell tumors with GLP-1 receptor agonists. Human relevance remains unconfirmed. People with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) are excluded from retatrutide trials and should not take the drug.

Severe Hypoglycemia

Standalone hypoglycemia on retatrutide is rare (0% in trials). The risk rises significantly when retatrutide is used alongside insulin or sulfonylureas — and is one of the most important practical retatrutide side effects to plan for in T2D patients.

Is Retatrutide Safe?

Across the available data, retatrutide side effects are common but predominantly mild-to-moderate, and the serious adverse event rate is comparable to placebo (4% in both arms). There is no observed signal for major cardiovascular events. Bone fracture and kidney stone concerns are real but tied to the velocity of weight loss rather than direct drug toxicity.

What is genuinely unknown:

Long-term retatrutide side effects beyond 72 weeks — Phase 3 trials are still ongoing
Off-target effects in non-trial populations — Phase 2 and 3 enrolled relatively healthy adults with obesity
Real-world adherence and tolerability outside the close monitoring of clinical trials

What is fair to say: the retatrutide side effects profile is heavier than tirzepatide but produces meaningfully greater weight loss. For most candidates, the trade-off is favorable, especially with slow titration and good GI side-effect management.

Frequently Asked Questions About Retatrutide Side Effects

What are the most common retatrutide side effects? Nausea, vomiting, diarrhea, constipation, and decreased appetite — all gastrointestinal. Phase 3 rates at 12 mg: 43.2% nausea, 33.1% diarrhea, 25.0% constipation, 20.9% vomiting.

Do retatrutide side effects go away? For most patients, yes. GI side effects peak during dose escalation and resolve within 1–2 weeks at a stable dose. Heart rate elevation peaks around week 24 and then declines. Dysesthesia can persist longer in a minority of patients.

Are retatrutide side effects worse than Ozempic or Mounjaro? At top doses, yes — somewhat. Nausea and vomiting rates are higher than tirzepatide. Dysesthesia is unique to retatrutide. The weight-loss benefit is also larger (24% vs 21% vs 15%).

Can retatrutide cause hair loss? Indirectly. The hair shedding most patients experience is telogen effluvium triggered by rapid weight loss, not a direct pharmacological retatrutide side effect. Adequate protein intake reduces severity.

Is dysesthesia from retatrutide permanent? No. Most cases resolve at stable dose or after discontinuation. It is rarely painful and rarely causes treatment discontinuation.

What should I do if retatrutide side effects are intolerable? Hold the current dose — don't escalate. Most prescribers extend the time at the current dose for an additional 4 weeks before retrying escalation. If side effects persist at the lower dose, a dose reduction is reasonable.

Are there long-term retatrutide side effects? Long-term data beyond 72 weeks is still being collected. Known longer-term concerns include bone density loss, lean mass loss, gallbladder disease, and the dose-dependent dysesthesia signal.

Is there a complete retatrutide side effects list? Yes — here is the full retatrutide side effects list ranked by Phase 3 TRIUMPH-4 frequency at 12 mg: nausea (43.2%), diarrhea (33.1%), constipation (25.0%), vomiting (20.9%), dysesthesia/altered skin sensation (20.9%), decreased appetite (~18%), abdominal pain (~10%), fatigue (~8%), and elevated heart rate (5–10 bpm average). Less common: gallbladder events, injection-site reactions, hair shedding (indirect, from rapid weight loss). The phrase "side effects of retatrutide" or the misspelling "retatrutide side affects" refers to this same list.

Are "GLP-3 retatrutide side effects" different from regular retatrutide side effects? No. "GLP-3" is an informal nickname for retatrutide because it activates three receptors (GLP-1, GIP, glucagon) versus one for semaglutide. It is the same molecule (LY3437943), so GLP-3 retatrutide side effects are identical to retatrutide side effects: GI symptoms dominate, dysesthesia is unique to retatrutide, heart rate rises 5–10 bpm on average.

Can retatrutide cause dehydration? Yes — dehydration is a recognized retatrutide dehydration side effect, secondary to the nausea, vomiting, and diarrhea that reduce fluid intake. The dehydration side effect of retatrutide is most likely during dose escalation when GI symptoms peak. Aim for 2–3L of water daily during titration weeks, and watch for dark urine, dizziness on standing, and persistent fatigue as early warning signs.

What are retatrutide injections side effects for women? Retatrutide injections side effects for women include the standard GI profile (nausea, vomiting, diarrhea, constipation) at rates similar to men, plus some patterns more commonly reported by female patients: menstrual irregularities, increased hair shedding from rapid weight loss, and breast tenderness in a minority. Phase 3 enrolled both sexes — outcome differences are modest, but symptom timing can vary across the menstrual cycle.

Are retatrutide for-women before-and-after side effects different from men? The before-and-after side effects pattern for women on retatrutide is broadly similar to men: GI symptoms peak during titration and resolve at maintenance dose. Worth noting for women specifically: higher reported rates of menstrual changes and hair shedding, both linked to rapid weight loss rather than direct drug action. Before-and-after journals from women on retatrutide commonly cite the first 6–8 weeks as the hardest GI period.

Can retatrutide cause irregular periods? Yes — retatrutide causing irregular periods is a known indirect side effect, primarily driven by rapid weight loss rather than a direct hormonal action of the drug. Reports include delayed cycles, shorter cycles, lighter flow, and missed periods. Most cases normalize within 2–4 cycles after weight loss plateaus. If irregular periods persist beyond 4–6 months at a stable maintenance dose, that warrants a hormonal workup with your prescriber.

Last reviewed: May 14, 2026